* Gamma-A Technologies Inc., of Herndon, Va., received a $99,981 grant from the National Institutes of Health, of Bethesda, Md., to support a feasibility study on use of human immunoglobulins (IgG), natural antibodies, for prevention of infections in burn patients. The company believes the direct application of IgG could be used to overcome antibiotic-resistant strains of bacteria.
* Sonus Pharmaceuticals Inc., of Bothell, Wash., said it marketing application for EchoGen (perflenapent injectable emulsion) was approved in Europe. EchoGen, a fluorocarbon-based ultrasound contrast agent, was cleared as a transpulmonary echocardiographic contrast agent for patients with suspected or established cardiovascular disease who previously had inconclusive non-contrast imaging studies. EchoGen microbubbles travel in the bloodstream and enhance the reflected ultrasound signal of the blood, resulting in improved images. Abbott Laboratories, of Abbott Park, Ill., is Sonus' marketing partner.
* Bio-Technology General Corp., of Iselin, N.J., received approval from the FDA to market BioLon for ophthalmic surgical procedures. Akron Inc., of Lincolnshire, Ill., will launch the product this year. BioLon, a 1 percent solution of sodium hyaluronate, is designed to protect the corneal endothelium during cataract extraction procedures, intraocular lens implantation and anterior segment surgery.
* Titan Pharmaceuticals Inc., of South San Francisco, started multicenter Phase II trials of CeaVac cancer vaccine for colorectal cancer and of TriAb cancer vaccine in breast cancer. Both are randomized and placebo-controlled with about 200 patients per study. CeaVac is designed to generate immune responses to CEA (carcinoembryonic antigen), which is expressed in a variety of cancers. TriAb is directed against the HMFG tumor associated antigen.